Growing investor interest sparks more funding for psychedelic clinical trials

The potential of psychedelics to treat a range of mental health conditions continues to attract increasing levels of funding for clinical trials as firms work towards bringing them into mainstream medical use.

Boston-based Preclinical neuroscience company Delix Therapeutics recently closed an initial Series A round of funding, in which it raised $70m for clinical trials of its psychoplastogen compounds.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Pablo Sharrock
+34 722 642 678
Email Pablo